Metformin is an antidiabetic drug that is used daily by millions of patients worldwide. Metformin is able to cross the blood-brain barrier and has recently been shown to increase glucose consumption and lactate release in cultured astrocytes. However, potential effects of metformin on mitochondrial tricarboxylic acid (TCA) cycle metabolism in astrocytes are unknown. We investigated this by mapping 13 C labeling in TCA cycle intermediates and corresponding amino acids after incubation of primary rat astrocytes with [U-13 C]glucose. The presence of metformin did not compromise the viability of cultured astrocytes during 4 hr of incubation, but almost doubled cellular glucose consumption and lactate release. Compared with control cells, the presence of metformin dramatically lowered the molecular 13 C carbon labeling (MCL) of the cellular TCA cycle intermediates citrate, a-ketoglutarate, succinate, fumarate, and malate, as well as the MCL of the TCA cycle intermediate-derived amino acids glutamate, glutamine, and aspartate. In addition to the total molecular 13 C labeling, analysis of the individual isotopomers of TCA cycle intermediates confirmed a severe decline in labeling and a significant lowering in TCA cycling ratio in metformin-treated astrocytes. Finally, the oxygen consumption of mitochondria isolated from metformintreated astrocytes was drastically reduced in the presence of complex I substrates, but not of complex II substrates. These data demonstrate that exposure to metformin strongly impairs complex I-mediated mitochondrial respiration in astrocytes, which is likely to cause the observed decrease in labeling of mitochondrial TCA cycle intermediates and the stimulation of glycolytic lactate production. V C 2017 Wiley Periodicals, Inc.
Metformin is an antidiabetic drug that is used daily by millions of patients worldwide. Metformin is able to cross the blood-brain barrier and has recently been shown to increase glucose consumption and lactate release in cultured astrocytes. However, potential effects of metformin on mitochondrial tricarboxylic acid (TCA) cycle metabolism in astrocytes are unknown. We investigated this by mapping 13 C labeling in TCA cycle intermediates and corresponding amino acids after incubation of primary rat astrocytes with [U-13 C]glucose. The presence of metformin did not compromise the viability of cultured astrocytes during 4 hr of incubation, but almost doubled cellular glucose consumption and lactate release. Compared with control cells, the presence of metformin dramatically lowered the molecular 13 C carbon labeling (MCL) of the cellular TCA cycle intermediates citrate, a-ketoglutarate, succinate, fumarate, and malate, as well as the MCL of the TCA cycle intermediate-derived amino acids glutamate, glutamine, and aspartate. In addition to the total molecular 13 C labeling, analysis of the individual isotopomers of TCA cycle intermediates confirmed a severe decline in labeling and a significant lowering in TCA cycling ratio in metformin-treated astrocytes. Finally, the oxygen consumption of mitochondria isolated from metformintreated astrocytes was drastically reduced in the presence of complex I substrates, but not of complex II substrates. These data demonstrate that exposure to metformin strongly impairs complex I-mediated mitochondrial respiration in astrocytes, which is likely to cause the observed decrease in labeling of mitochondrial TCA cycle intermediates and the stimulation of glycolytic lactate production. V C 2017 Wiley Periodicals,
INTRODUCTION
Type 2 diabetes mellitus is a disease that affected around 382 million people worldwide in 2013 (Guariguata et al., 2014) . Because metformin efficiently lowers blood glucose concentration (Scarpello and Howlett, 2008; Rios et al., 2015) , it is taken by more than 100 million patients daily (Viollet et al., 2012) . Metformin is not metabolized but, instead, removed from the human body by renal excretion (Gong et al., 2012) . Although metformin is considered a safe antidiabetic drug, incidences of lactic acidosis have been reported in metformin-treated patients (Bolen et al., 2007) , and this has been connected SIGNIFICANCE Metformin is an antidiabetic drug that increases glycolysis in astrocytes. The present study shows by using [U- 13 C]glucose and metabolic mapping that the tricarboxylic acid cycle activity is significantly lowered upon metformin treatment in astrocytes. Oxygen consumption is strongly lowered in the presence of complex I substrates in mitochondria isolated from metformin-treated astrocytes. Thus, mechanistically, the decreased tricarboxylic acid cycle and increased glycolytic activity in metformin-treated cultured astrocytes are likely to be consequences of an inhibition of complex I-mediated respiration.
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with a high mortality risk (Kajbaf and Lalau, 2014; Huang et al., 2015) . Concerning neurological consequences, diabetic patients have an increased risk of stroke or vascular dementia, and metformin treatment has been reported to decrease this risk (Patrone et al., 2014) . In contrast, for a population of long-term metformin-treated patients, an increased risk of developing Alzheimer disease has been reported, whereas the treatment with other antidiabetic drugs was not associated with this increased risk (Imfeld et al., 2012) .
Metformin has been reported to cross the bloodbrain barrier, and the concentrations of metformin determined for the cerebrospinal fluid are even higher than those in blood plasma (Labuzek et al., 2010b) . Astrocytes are the most abundant glial cell type in the brain (Nedergaard et al., 2003; Gonzalez-Perez et al., 2015) . Because astrocytes cover the brain capillaries almost completely with their endfeet, these cells are in contact with glucose and every other substance that crosses the blood-brain barrier from blood into the brain (Parpura and Verkhratsky, 2012) . Accordingly, astrocytes are considered to have a variety of important regulatory and homeostatic functions-for example, in cerebral glucose metabolism (Belanger et al., 2011; Hirrlinger and Dringen, 2010) and in the defense of the brain against oxidative stress and toxins (Dringen et al., 2015 (Dringen et al., , 2016 Schreiner et al., 2015) . Recent studies on cultured astrocytes have demonstrated that metformin augments the formation of ketone bodies (Takahashi et al., 2014) and reduces ammonia-induced release of thrombospondin 1 (Jayakumar et al., 2014) . In addition, metformin has been reported to increase glycolytic flux in cultured rat and mouse astrocytes (Allaman et al., 2015; Westhaus et al., 2017) . For various peripheral cell lines and for isolated mitochondria, it has been reported that metformin lowers tricarboxylic acid (TCA) cycle activity and mitochondrial respiration (Fendt et al., 2013; Andrzejewski et al., 2014; Bridges et al., 2014) . For rat liver mitochondrial lysates, metformin has been shown to inhibit the activity of mitochondrial glycerophosphate dehydrogenase, causing an altered redox state that reduces the use of lactate as a substrate for the production of glucose via gluconeogenesis (Madiraju et al., 2014) . The first evidence that metformin also affects mitochondrial function in brain cells was recently provided by a report showing that metformin decreases the oxygen consumption rate in primary mixed glial cells from Abcd1-KO mice (Singh et al., 2016) .
To elucidate a potential mitochondrial contribution in the reported stimulation by metformin of the glycolytic flux in cultured astrocytes (Allaman et al., 2015; Westhaus et al., 2017) , we have now studied the effects of metformin on the mitochondrial metabolism of astrocytes by two methological approaches. First, we incubated cultured astrocytes with uniformly labeled 13 C glucose in the absence or the presence of metformin and tracked the formation of 13 C-labeled metabolites by gas chromatography mass spectrometry (GCMS). This approach revealed that metformin strongly decreased the incorporation of 13 Clabeled carbon into intermediates of the TCA cycle and corresponding amino acids. In a second approach, we investigated the respiration of mitochondria isolated from metformin-incubated cultured astrocytes and observed an impaired mitochondrial respiration in the presence of complex I substrates. In summary, our data demonstrate for the first time that metformin severely decreased complex I-dependent mitochondrial respiration and TCA cycle activity in cultured astrocytes.
MATERIALS AND METHODS

Materials
Dulbecco's modified Eagle's medium (DMEM) was purchased from Invitrogen-Gibco (Darmstadt, Germany), and fetal calf serum (FCS) and penicillin G/streptomycin sulfate solution were from Biochrom (Berlin, Germany). D-Glucose-13 C 6 (99% enrichment) was obtained from Cambridge Isotope Laboratories (Andover, MA). Metformin was obtained from Sigma-Aldrich (Steinheim, Germany). N-methyl-N-(tert-butyldimethylsilyl) trifluoroacetamide (MTBSTFA) and N,N-dimethylformamide (DMF) were purchased from Sigma-Aldrich (St. Louis, MO). The enzymes glucose-6-phosphate dehydrogenase, hexokinase, lactate dehydrogenase (LDH), and glutamate pyruvate transaminase were purchased from Roche Diagnostics (Mannheim, Germany). GCMS chemicals and columns were obtained from Agilent Technologies (Santa Clara, CA). Other chemicals and buffer ingredients were purchased from Sigma (Steinheim, Germany), Applichem (Darmstadt, Germany), or Merck (Darmstadt, Germany). Sterile Nunclon 5-cm cell culture dishes and nonsterile 96-well plates were from Sarstedt (N€ umbrecht, Germany); 175 cm 2 cell culture flasks were purchased from Thermo Fischer (Waltham, MA).
Astrocyte Cultures
Astrocyte-rich primary cultures were prepared using the whole brains of newborn Wistar rats as described previously (Hamprecht and L€ offler, 1985; Tulpule et al., 2014) . The rats were bred and mated in an animal facility of the University of Bremen (Germany) with a 12-hr light/12-hr dark cycle. All rats had ad libitum access to standard chow and water. For culture preparation, the brains from male and female newborn rats of one litter were combined and mechanically disrupted. The harvested cells were seeded at a density of 3,000,000 viable cells in 5 ml culture medium (90% DMEM containing 25 mM glucose, 10% FCS, 1 mM pyruvate, 18 U/ml penicillin G, and 18 mg/ml streptomycin sulfate) in 5-cm cell culture dishes. Alternatively, 30,000,000 isolated cells were seeded in 50 ml culture medium in 175 cm 2 culture flasks. The cultures were grown in the humidified atmosphere of a Sanyo (Osaka, Japan) incubator with 10% CO 2 . The culture medium was renewed every seventh day and 1 day before the experimental incubation. Confluent cultures of an age between 14 and 30 days were used for metabolic labeling experiments. The cultures in flasks were used for the isolation of mitochondria after 30 or 31 days in culture. Astrocyte-rich primary cultures are strongly enriched in astrocytes but contain minor contaminations of oligodendrocytes and microglial cells (Petters and Dringen, 2014; Tulpule et al., 2014) .
Experimental Incubations
Metabolite 13 C labeling experiments were performed using primary cultures of astrocytes in 5-cm dishes. For each experiment, three dishes from one culture (technical replicates) were used per condition (control and metformin). Each experiment was repeated twice on independently prepared cultures (n 5 3). For incubations, the culture medium was removed and the cultures were washed once with 3 ml prewarmed (378C) incubation buffer (IB; 145 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 0.8 mM Na 2 HPO 4 , 20 mM HEPES adjusted at 378C to pH 7.4 with NaOH) and incubated for 4 hr at 378C in 2.5 ml IB without (controls) or with 10 mM metformin and in both cases (control and metformin) with 5 mM [U-13 C]glucose. This high concentration of metformin and this short incubation time were selected because these conditions were reported to acutely double glycolytic flux in viable astrocytes cultured in wells of 24-well dishes (Westhaus et al., 2017) . Furthermore, under those conditions the stimulating effect of metformin on glycolysis was persistent even after removal of metformin (Westhaus et al., 2017) . After the incubation, the incubation media were harvested and used to determine extracellular LDH activity, the extracellular concentrations of glucose and lactate, and the 13 C labeling in extracellular lactate and alanine. The cells were washed with 1.5 ml ice-cold phosphatebuffered saline (10 mM potassium phosphate buffer pH 7.4 containing 150 mM NaCl) and extracted with ethanol (Walls et al., 2014) for analysis of 13 C-labeled TCA cycle intermediates and amino acids.
Extraction of Cell Cultures for GCMS Measurement
The washed cells were extracted as previously described (Walls et al., 2014) . To each dish of washed cells, 1.5 ml icecold 70% ethanol was applied and the cells were scraped off using a rubber policeman. The lysate was transferred into a 2-ml reaction tube, the dish was washed with an additional 500 ml 70% ethanol, and the ethanol fractions of one dish were combined and mixed. After centrifugation for 20 min at 48C at 12,100g (Eppendorf MINI-Spin, Hamburg, Germany), the supernatant was transferred into a new reaction tube and dried in a speed-vac (Eppendorf, Hamburg, Germany) at room temperature, while the centrifugation pellets were dried overnight on air and used for protein determination.
Metabolic Mapping of Metabolites of Interest by GCMS
Dried cell extracts from one dish and dried media samples (from 1 ml incubation medium) were resuspended in 250 and 400 ml pure H 2 O, respectively. One hundred twenty-five microliters of the resuspended cell extracts or media samples were used for GCMS analysis. Extraction and derivatization of samples was performed by modified version of a previously described method (Mawhinney et al., 1986; Walls et al., 2014) . Briefly, the GCMS aliquot was adjusted to pH 1-2 with 2 M HCl and dried under nitrogen flow. Organic extraction with 96% ethanol/benzene and drying under nitrogen flow was performed twice, followed by derivatization of metabolites with 14% DMF/86% MTBSTFA. Analysis of unlabeled standards, cell extracts, and media samples was performed on a gas chromatograph (Agilent Technologies 7820A chromatograph, J&W GC column HP-5MS, part no. 19091S-433; Agilent, Glostrup, Denmark) coupled to a mass spectrometer (Agilent Technologies, 5977E). The isotope enrichment of the metabolites of interest was calculated by a published method and corrected for natural abundance of 13 C by using the unlabeled standards (Biemann, 1962) . The data are presented for each isotopomer M1X (M 5 mass of the unlabeled molecule, X 5 number of labeled carbon atoms) as percentage of the total pool of the metabolite. An overview of the metabolite labeling patterns expected to occur after metabolism of [U-13 C]glucose during glycolysis and up to three turns of the TCA cycle is shown in Fig. 1 .
Calculation of Molecular Carbon Labeling
The average percentage of labeled carbon atoms for each metabolite was calculated (Bak et al., 2006) . For example, lactate contains three carbon atoms, and it may contain between one and three 13 C atoms (M11, M12, or M13). The percentage of the individual isotopomers (i.e., M11, M12, or M13) is multiplied by the number of carbons labeled (i.e., 1 for M11, 2 for M12, or 3 for M13); the result is summed up and expressed as a percentage of the total number of carbon atoms. Here is one example calculation of the cellular lactate molecular carbon labeling (MCL): lactate is labeled as follows: M11, 3%; M12, 5%; and M13, 67%; the calculation will be: ððM11; 3% 3 1Þ 1 ðM12; 5% 3 2Þ 1 ðM13; 67% 3 3ÞÞ=300 3 100% 5 71%:
Thus, the percent MCL labeling is a measure of the total labeling of lactate carbons or any other metabolite.
Calculation of the Cycling Ratio
The cycling ratio is a measure of TCA cycle activity (Bak et al., 2012) . C]acetyl-CoA condenses with unlabeled oxaloacetate, leading to double labeling (M12) of TCA cycle intermediates and derived amino acids. Glutamate is formed either by transamination or reductive amination of aketoglutarate (a-KG) (Fig. 1) . In subsequent turns of the TCA cycle, [1,2-13 C]acetyl-CoA condenses with already labeled oxaloacetate, and TCA cycle intermediates and derived amino acids will be labeled in more than two positions. The cycling ratio as a measure of TCA cycle activity is calculated by dividing the labeling arising from second and later turns (i.e., metabolites either monolabeled or labeled in more than 2 positions) with that from the first turn using the following formula from the percent labeled isotopomer (I) of each metabolite (given is the example for glutamate):
Cycing ratio ðglutamateÞ
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If the labeling arising from second or later turns of the TCA cycle is decreasing by a given treatment, or the labeling arising from the first turn of the TCA cycle is increasing, the cycling ratio is decreased. Thus, a lower cycling ratio means a slower TCA cycle activity within a given time frame.
Determination of Cell Viability and Protein Content
To estimate a potential loss in cell membrane integrity of cultured astrocytes by a given treatment, the release of the cytosolic enzyme LDH was determined as previously described (Dringen et al., 1998; Tulpule et al., 2014) using 10-ml samples of the harvested incubation media. Briefly, the LDH activities in media and cell lysates from untreated (initial) cells were determined before the incubation, and the values obtained were used as blank and as 100% value, respectively. The initial cells were lysed for 30 min at room temperature in 2.5 ml 1% (v/v) Triton X-100 in IB per dish. The LDH activities measured in the media samples after the experimental incubations were expressed as percentage of the initial cellular LDH activity (Fig. 2) . The protein content was determined by the Lowry method (Lowry et al., 1951) from the dry pellets obtained after the extraction. The pellets were lysed in 1 ml 0.5 M NaOH for 1 hr on a shaker, and 50 ml of lysate was used in the assay. The determination was based on bovine serum albumin (BSA) as standard protein. The protein content of astrocytes that had been incubated in the absence and the presence of 10 mM metformin for 4 hr were 0.99 6 0.04 mg/dish and 1.00 6 0.06 mg/ dish and did not differ significantly. The extracellular LDH activities and protein contents were determined for the dishes that had been used for the experimental incubations with [U-
13 C]glucose and are given as mean 6 standard deviation of values obtained from experiments performed on three independently prepared cultures (n 5 3).
Determination of Extracellular Lactate and Glucose Concentrations
Extracellular glucose was determined in 10-ml media samples by a coupled enzymatic assay with hexokinase and glucose-6-phosphate dehydrogenase as previously described (Tulpule et al., 2014) . Glucose consumption was calculated from the difference of the glucose concentration in the media collected before and after incubation with cells. Extracellular lactate was quantified in 20-ml media samples by a coupled enzymatic assay with LDH and glutamate pyruvate transaminase as previously described (Tulpule et al., 2014) .
Isolation of Mitochondria and Determination of Mitochondrial Oxygen Consumption
Astrocytes grown in a 175 cm 2 flasks were washed with 20 ml 378C prewarmed IB and incubated at 378C for 4 hr in 20 ml IB in the absence or presence of 10 mM metformin. After incubation, the media were collected for determination of the extracellular concentrations of lactate and glucose. Mitochondria were isolated from the cultures as recently described (Brandmann et al., 2013) . Briefly, the cells were washed with 13 ml ice-cold mitochondria isolation buffer (MIB, 145 mM KCl, 30 mM HEPES, 5 mM KH 2 PO 4 , 3 mM MgCl 2 , 0.1 mM EGTA, 0.1% BSA, pH 7.4). Subsequently, the cells were lysed with 10 ml of a 100 mg/ml digitonin solution in MIB for 10 min on ice. The lysate was scraped off the flask and centrifuged (15 min, 12,000g, 48C). The pellets containing the mitochondria were carefully resuspended in MIB and distributed in 150-ml aliquots. The experiments on oxygen consumption were performed on mitochondria harvested from one flask each C]glucose (M16). Glycolysis converts glucose M16 to pyruvate M13, which is decarboxylated to acetyl (M12)-CoA by pyruvate dehydrogenase. The entrance of acetyl (M12)-CoA into the TCA cycle generates a complex labeling pattern in TCA cycle intermediates and subsequently of the amino acids aspartate or glutamate, which are formed by transamination of oxaloacetate and aketoglutarate, respectively. Metabolites generated directly during the first turn of the TCA cycle are written in bold, those generated in the second turn of the TCA cycle are written in normal style, and metabolites generated after the second turn of the TCA cycle are written in italics. (M 5 mass of the unlabeled molecule; X 5 number of labeled carbon atoms). The labeling patterns after further turns of the TCA cycle will be indistinguishable from the labeling shown here, because already after the second turn, almost all carbon atoms of the metabolites are labeled. Thus, further labeling will result only in the exchange of a labeled carbon with a new labeled carbon, which cannot be documented by GCMS analysis. Pyruvate carboxylase converts pyruvate into oxaloacetate. Subsequent labeling arises from oxaloacetate condensing with unlabeled acetyl-CoA, and afterwards direct TCA cycle metabolism is shown in the brackets. In addition, oxaloacetate can be converted via malate to the fumarate (back cycling). Because fumarate is a symmetrical molecule, the labeling is scrambled (e.g., [1, 2, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]fumarate gives rise to [2, 3, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]fumarate). The labeling in fumarate (M13) is indistinguishable by the GCMS method, but after cycling in the TCA cycle will form the M12 and M13 aketoglutarate.
for incubations without and with metformin per culture. In each experiment, the measurements of oxygen consumption were carried out on three aliquots of the mitochondrial preparations (technical replicates). The experiments were reproduced twice on independently prepared cultures (n 5 3).
Oxygen consumption measurements were performed as described previously using an Oxygraph DW1/AD (Hansatech Instruments, Norfolk, UK) (Brandmann et al., 2013) in the absence of metformin. For complex I-related measurements, 2.5 mM malate, 2.5 mM glutamate, and 0.5 mM ADP were applied, while complex II-related oxygen consumption was investigated in the presence of 2.5 mM succinate and 0.5 mM ADP. For all reactions, oxygen consumption was recorded for 4 min after adding 150 ml mitochondrial suspension in a total chamber volume of 1 ml. The respiratory control ratios (RCRs) were calculated by dividing the specific oxygen consumption in the presence of ADP by the specific oxygen consumption in the absence of ADP (resting state).
The oxygen consumption rates (nmol O 2 /min) were normalized to the protein content of isolated mitochondrial fractions. The protein content of the mitochondrial preparations was determined for the mitochondrial pellet obtained by centrifugation (15 min, 12,000g, 48C) of two mitochondrial aliquots per culture flask used. The centrifugation was required to remove the BSA-containing supernatant. The pellet was lysed in 200 ml 0.5 M NaOH before the protein content was determined using the Lowry method using BSA as a standard protein (Lowry et al., 1951) .
Presentation of Data
The data obtained are presented as mean values 6 standard deviation of values obtained from three independently prepared cultures (n 5 3). All data obtained were used for statistical analysis, and the significance of differences between two sets of data was calculated by the one-tailed paired t-test by the software Graphpad Prism (Research Resource Identifier (RRID): SCR_002798). During the analysis, the authors knew which conditions were control or treatment conditions. Because of the small number, a test for normality distribution of the data obtained was not possible. P > 0.05 was considered not significant.
RESULTS
Effect of Metformin on the Viability and the Glycolysis of Cultured Astrocytes
To test whether metformin affects glucose metabolism in cultured astrocytes, the cells were incubated with 5 mM [U-13 C]glucose in the absence or presence of 10 mM metformin for 4 hr. Exposure of cultured astrocytes to 10 mM metformin for 4 hr did not affect the viability of the cells as shown by the absence of any increase in the extracellular activity of the cellular enzyme LDH (Fig. 2A) . However, the presence of metformin significantly increased the basal release of lactate from the cells from 2.11 6 0.03 mmol/mg protein (control cells) to 3.80 6 0.06 mmol/mg protein (metformin-treated cells; P < 0.01) (Fig. 2B) . In addition, the amount of glucose consumed within 4 hr by the cells increased from 1.32 6 0.07 mmol/mg protein (control cells) to 2.27 6 0.07 mmol/mg protein (P < 0.01) in the presence of metformin (Fig. 2C) . These results obtained in astrocyte cultures on 5-cm dishes confirm literature data reported for astrocytes C]glucose in the absence or presence of 10 mM metformin for 4 hr, and extracellular LDH activity (A), lactate released (B), and extracellular glucose consumed (C) were determined. Glucose consumption was calculated from the difference of the glucose concentrations in the media collected before and after incubation with cells. The data shown are mean 6 SD of values obtained on three independently prepared cultures (n 5 3) in 5-cm dishes. Significance of differences between the values obtained for cells treated in the absence and the presence of metformin was calculated by t-test (***P < 0.001).
that had been incubated with or without metformin in 24-well cell culture dishes (Westhaus et al., 2017) with another medium-to-cell ratio.
Molecular
C Labeling of Lactate and Alanine
Astrocytes take up and metabolize [U-
13
C]glucose via glycolysis to pyruvate M13 (Fig. 1) , which may subsequently be reduced to lactate or transaminated to alanine. The MCL of cellular lactate was almost identical in control astrocytes (71.6% 6 6.4%) and metformin-treated astrocytes (73.9% 6 8.1%; P 5 0.15) (Fig. 3A) , while the MCL of cellular alanine slightly decreased from 58.7% 6 5.8% (control cells) to 50.4% 6 5.0% (metformin-treated cells; P 5 0.06) (Fig. 3B) . Analysis of the metabolites released from the cells into the incubation medium revealed that the MCL of both extracellular lactate and alanine were slightly, and in the case of lactate significantly, increased from 84.7% 6 1.3% to 89.9% 6 0.4% (P < 0.01) and 60.2% 6 1.0% to 63.3% 6 1.3% (P 5 0.05), respectively, after exposure to metformin compared with control incubations in the absence of metformin (Fig. 3C, D) . Cultured astrocytes in 175 cm 2 flasks were incubated without (control) or with 10 mM metformin. Mitochondria were isolated from the same astrocytes, and the specific oxygen consumption of mitochondria in the absence of ADP (resting state) and presence of 0.5 mM ADP (data in Fig. 8C ) was calculated from the linear decrease of oxygen levels determined in the absence or presence of substrates for complex I (2.5 mM malate and 2.5 mM glutamate) or complex II (2.5 mM succinate) and normalized to the protein content of the mitochondrial fraction. The respiratory control ratios (RCRs) were calculated by dividing the specific oxygen consumption determined for the presence of ADP by the specific oxygen consumption determined for the absence of ADP (resting state). The results represent mean 6 SD data obtained in experiments performed on mitochondria isolated from three independently prepared astrocyte cultures (n 5 3). The significance of differences between the data obtained for cells treated in the absence and presence of metformin was calculated by one-tailed paired t-test.
Labeling of Cellular TCA Cycle Intermediates and Amino Acids
To investigate the influence of metformin on TCA cycle activity, we determined the 13 C labeling of TCA cycle intermediates derived from [U-13 C]glucose. The MCL of the five measured TCA cycle intermediates (a-KG, succinate, fumarate, malate) was highly significantly decreased (with the exception of citrate) after incubation with metformin to MCL values, representing 49% 6 20% (citrate; P 5 0.07), 27% 6 14% (a-KG; P < 0.01), 16% 6 6% (succinate; P < 0.01), 23% 6 5% (fumarate; P 5 0.02), and 31% 6 9% (malate; P 5 0.01) of the respective MCL values determined for control incubations in the absence of metformin (Fig. 4) .
The isotopomer patterns were analyzed in detail for the two TCA cycle intermediates a-KG (Fig. 5A) and malate (Fig. 5B) . The percent labeling of all five a-KG isotopomers M11 (P 5 0.01), M12 (P < 0.01), M13 (P < 0.01), M14 (P 5 0.04), and M15 (P 5 0.02; Fig.  5A ) and of all four malate isotopomers M11 (P < 0.01), M12 (P < 0.01), M13 (P 5 0.03), and M14 (P 5 0.02; Fig. 5B ) were significantly lowered in metformin-treated astrocytes compared with control cells.
In addition to the TCA cycle intermediates, the amino acids derived from TCA cycle intermediates (i.e., glutamate and glutamine from a-KG and aspartate from oxaloacetate) showed a severely lowered MCL (glutamate: P < 0.01; glutamine: P 5 0.02; aspartate: P < 0.01) compared with that of control cells (Fig. 6A) . Analysis of the different isotopomers of glutamate ( Fig. 7A ; M11: P < 0.01; M12; P < 0.01; M13: P 5 0.01; M14: P 5 0.01; M15: P 5 0.01), glutamine ( Fig. 7B ; M11: P 5 0.01; M12; P 5 0.03; M13: P 5 0.05; M14: P 5 0.05; M15: P 5 0.07), and aspartate ( Fig. 7C ; M11: P < 0.01; M12; P < 0.01; M13: P < 0.01; M14: P < 0.01) revealed that the 13 C labeling of all isotopomers was significantly lowered to values between 9% and 35% of the values determined for control cells (Fig. 7) .
The labeling in a-KG M12 and malate M12 was 17.7% 6 1.5% and 18.0% 6 1.6%, respectively, in control astrocytes (Fig. 5) . The labeling observed in the TCA cycle-derived amino acids was comparable, with 19.6% 6 1.5% in glutamate, 13.8% 6 5.4% in glutamine, and 14.8% 6 1.2% in aspartate (Fig. 7) . Thus, the percent labeling observed in control astrocytes is reflected in the TCA cycle-derived amino acids glutamate and aspartate. The slightly lower labeling in glutamine M12 compared C]glucose in the absence or presence of 10 mM metformin. The cell extracts were analyzed by GCMS for the percent increase in MCL of the indicated metabolites. The data shown are mean 6 SD of values obtained on three independently prepared cultures (n 5 3). Significance of differences between the values obtained for cells treated in the absence and the presence of metformin was calculated by t-test (***P < 0.001, **P < 0.01, *P < 0.05). citr, citrate; a-KG, a-ketoglutarate; succ, succinate; fum, fumarate; mal, malate. Significance of differences between the values obtained for cells treated in the absence and presence of metformin was calculated by ttest (*P < 0.05, **P < 0.01, ***P < 0.001). a-KG, a-ketoglutarate.
with glutamate M12 may be due to the enzymecatalyzed amidation by glutamine synthetase of glutamate to glutamine. In metformin-treated astrocytes, the M12 labeling in a-KG and malate was reduced to 4.8% 6 2.9% and 5.4% 6 1.2% and, in the amino acids, to 5.7% 6 0.3% (glutamate), 5.5% 6 0.3% (glutamine), and 3.0% 6 0.4% (aspartate). These data suggest that the labeling observed in the TCA cycle intermediates of metformin-treated astrocytes is also reflected in the corresponding amino acids.
Pyruvate carboxylation is observed in our data as direct labeling of malate M13 and a-KG M13 (see Fig.  1 for labeling patterns) . The relative metformindependent decline in malate M13 is smaller compared with the relative metformin-dependent decline in a-KG M13, which may be due to the entrance of labeling by Fig. 6 . Effects of metformin on the molecular carbon labeling (MCL) of amino acids derived from TCA cycle intermediates (A) and on the cycling ratio (B) in cultured astrocytes. The cells were exposed to 5 mM [U-13 C]glucose in the absence or presence of 10 mM metformin for 4 hr. The cell extracts were analyzed by GCMS for the percent increase in MCL of the indicated amino acids. The data shown are mean 6 SD values obtained on three independently prepared cultures (n 5 3). Significance of differences between the values obtained for cells treated in the absence and presence of metformin was calculated by the t-test (*P < 0.05, **P < 0.01, ***P < 0.001). glu, glutamate; gln, glutamine; asp, aspartate. C-labeled isotopomers of glutamate (A), glutamine (B), and aspartate (C). The data shown are mean 6 SD values obtained on three independently prepared cultures (n 5 3). Significance of differences between the values obtained for cells treated in the absence and presence of metformin was calculated by t-test (*P < 0.05, **P < 0.01, ***P < 0.001).
pyruvate carboxylation. The entrance of labeled carbon via pyruvate carboxylation is independent of the redox state, but dependent on ATP. Thus, the labeling of malate M13 via pyruvate carboxylation is redox independent, but ATP dependent. The pyruvate carboxylationdependent labeling of a-KG M13 is dependent on the redox state, because of the prior reaction catalyzed by isocitrate dehydrogenase. The minor differences in malate M13 and a-KG M13 (via pyruvate carboxylation) compared with the larger differences in malate M12 and a-KG M12 (primarily via pyruvate dehydrogenase [PDH] ) may indicate that the entrance of carbon into the TCA cycle via PDH may be more affected by metformin treatment compared with the entrance via pyruvate carboxylation.
Cycling Ratio
The TCA cycling ratio was calculated from the labeling of the individual isotopomers as described in the Methods for the three TCA cycle-derived amino acids glutamate, glutamine, and aspartate. Compared with control cells (incubated in the absence of metformin), the cycling ratios were significantly decreased to 57%, 49%, and 81% for glutamate (P < 0.01), glutamine (P 5 0.11), and aspartate (P 5 0.01), respectively, in astrocytes incubated with metformin (Fig. 6B) . For the TCA cycle intermediates, only the cycling ratio of malate was significantly (P < 0.05) decreased from 1.4 6 0.1 in control cells to 1.2 6 0.1 in metformin-treated cells (P 5 0.04), while no significant difference was observed for the cycling ratios of citrate, a-KG, succinate, and fumarate (data not shown). These data indicate that the entrance of carbon from glucose into the TCA cycle is decreased and that the activity of the TCA cycle itself may be slightly reduced.
Mitochondrial Oxygen Consumption
To test for an effect of metformin on mitochondrial oxygen consumption, astrocyte cultures were incubated with or without 10 mM metformin for 4 hr, and subsequently, mitochondria were isolated and tested for complex I-or complex II-driven oxygen consumption. Also in the experiments with astrocytes in 175 cm 2 flasks with another medium-to-cell ratio, the presence of metformin significantly increased cellular lactate release ( Fig. 8A ; P 5 0.01) and cellular glucose consumption ( Fig. 8B ; P 5 0.01) compared with control cells incubated in the absence of metformin. The oxygen consumption rate in the resting state (absence of ADP; Table I ) was lower than in the presence of ADP (Fig. 8C) , and the RCR (Table I) was high as expected for healthy mitochondria and as reported before (Almeida and Medina, 1997) . The oxygen consumption of mitochondria isolated from metformin-exposed astrocytes was significantly reduced in the presence of complex I substrates ( Fig. 8C ; P 5 0.04). In contrast, in the presence of the complex II substrate succinate, no difference in respiration was observed between mitochondria that had been isolated Fig. 8 . Effects of an incubation of cultured astrocytes with metformin on glycolysis and mitochondrial oxygen consumption. Cells in 175 cm 2 flasks were incubated for 4 hr without (control) or with 10 mM metformin. The incubation media were collected, and the concentration of extracellular lactate (A) and the consumption of extracellular glucose (B) were determined. Glucose consumption was calculated from the difference of the glucose concentrations in the media collected before and after incubation with cells. Mitochondria were isolated from the same astrocytes that had been incubated without (control) or with 10 mM metformin. The specific oxygen consumption of mitochondria in the presence of 0.5 mM ADP was calculated from the linear decrease of oxygen levels determined in the absence or presence of substrates for complex I (2.5 mM malate and 2.5 mM glutamate) or complex II (2.5 mM succinate; C) and normalized to the protein content of the mitochondrial fraction. The results represent mean 6 SD data obtained in experiments performed on cells and mitochondria isolated from three independently prepared astrocyte cultures (n 5 3). The significance of differences between the data obtained for cells treated in the absence and presence of metformin was calculated by t-test (*P < 0.05, **P < 0.01).
from metformin-treated and control astrocytes ( Fig. 8C ; P 5 0.23).
DISCUSSION
The antidiabetic drug metformin is used to treat more than 100 million patients worldwide (Viollet et al., 2012) . As metformin has been reported to enter and accumulate in the brain as well as in the cerebrospinal fluid (Labuzek et al., 2010b) , it is important to investigate potential effects of metformin on brain cell metabolism. Indeed, several studies suggest that metformin may be beneficial in neurodegenerative diseases (Ma et al., 2007; Nath et al., 2009 ) and stroke . There is currently no evidence of potential adverse consequences of an exposure of brain cells to metformin, and even incubations of cultured astrocytes for 24 hr with 10 mM metformin did not compromise cell viability (Westhaus et al., 2017) . However, we found a drastic and highly significant decrease in the labeling of TCA cycle intermediates formed after application of [U-13 C]glucose, demonstrating that metformin can severely affect the mitochondrial metabolism in cultured astrocytes as reported before for peripheral cell lines (Fendt et al., 2013; Andrzejewski et al., 2014; Janzer et al., 2014) . The MCL and all detected isotopomers for each TCA cycle intermediate and amino acid were at least slightly decreased, although these reductions did not reach significance in all cases. This clearly demonstrates that not only one specific enzymatic pathway is decreased in metformin-treated astrocytes but that the overall TCA cycle metabolism of these cells was impaired.
The concentration of metformin applied in our study is high compared with the micromolar concentrations of metformin (Hussey et al., 2013; Kajbaf and Lalau, 2013; Lalau et al., 2011; DeFronzo et al., 2016; El Messaoudi et al., 2016) found in plasma from metformintreated patients. However, after long-term treatment at least of mice, the tissue metformin concentration has been reported to reach up to 4 mM (Wilcock and Bailey, 1994) . Millimolar concentrations of metformin have also been used previously for studies on the effects of metformin on cultured neurons (24-48 hr, 10 mM [Chau- Van et al., 2007] ), microglial cells (2 hr with 2-4 mM metformin [Labuzek et al., 2010a] ), and peripheral cells (24-72 hr, 1-10 mM [Lee et al., 2014; Chen et al., 2015b; Smieszek et al., 2015] ). The discrepancy between the experimental concentrations of metformin used in vitro and in vivo and the definition of a reasonable "therapeutic" concentration has been recently discussed in detail (He and Wondisford, 2015; Kajbaf et al., 2016) . Kajbaf and colleagues (2016) report a wide range of therapeutic plasma concentrations of metformin in the literature. Furthermore, this study recommends a dose-efficiency study to measure the plasma metformin concentration that corresponds to the therapeutic metformin concentration (Kajbaf et al., 2016) . However, it should also be mentioned here that during longer incubations of cultured astrocytes for 24 hr, already the presence of 1 mM metformin is sufficient to double glycolytic lactate production (Westhaus et al., 2017) .
For acute experiments on rat astrocytes in the hour range, the application of 3 to 10 mM metformin was required to affect metabolic processes, most likely because uptake of metformin in these cells is slow. This view is supported by the observations that i) the onset of the stimulation of glycolysis requires more than 1 hr; ii) during longer incubations for 24 hr, already 1 mM metformin doubled glycolytic flux in astrocytes; iii) the hydrophobic metformin derivative phenformin is around 100-fold more potent than metformin to acutely stimulate astrocytic glycolysis; and iv) the stimulating effect of metformin on glycolysis is not abolished by removal of extracellular metformin, contrasting the situation observed for other glycolysis-stimulating substances (Westhaus et al., 2017) .
The uptake of metformin in peripheral cells is mediated by organic cation transporters (OCTs) (Nies et al., 2011; Oshima et al., 2015) , but the type of OCT expressed and even genetic polymorphism in one type of OCT affect cellular metformin uptake and action in mice and humans (Chen et al., 2015a; Hou et al., 2015; Futatsugi et al., 2016) . In cultured astrocytes, OCT2 and 3 were shown to be expressed (Cui et al., 2009; PerdanPirkmajer et al., 2012) , but inhibitors of OCT3 were unable to lower the metformin-induced stimulation of astrocytic glycolysis (Westhaus et al., 2017) , suggesting that these transporters may not be involved in metformin uptake into rat astrocytes. High concentrations of metformin may be required to allow at least some uptake of metformin by other pathways into the cells to generate intracellular concentrations sufficiently high to modulate mitochondrial metabolism of astrocytes. To address such questions, uptake studies should be performed to test for the potential involvement of OCTs in metformin uptake in astrocytes. Furthermore, astrocytes should be exposed for longer incubation times with metformin in lower concentrations to test whether this will cause sufficient cellular metformin concentrations to modulate mitochondrial metabolism and to confirm the data obtained for glycolysis stimulation by metformin (Westhaus et al., 2017) .
Moreover, compared with rat astrocytes, which require 3 mM metformin for half-maximal stimulation of glycolytic flux (Westhaus et al., 2017) , already 200 mM metformin causes half-maximal stimulation of glycolytic flux in mouse astrocytes (Allaman et al., 2015) . This suggests species-specific differences in the sensitivity of astrocytes toward metformin. It would be highly interesting to investigate the concentration range in which metformin may affect glycolysis and mitochondrial metabolism in human astrocytes.
Pyruvate produced by glycolysis in astrocytes is either reduced to lactate by LDH, which regenerates the NAD 1 required for continuous glycolytic flux, or is imported for oxidative degradation into mitochondria (Gray et al., 2014) . For peripheral cells, the metformininduced accelerated glycolytic flux and increased lactate release have been considered to cause a decreased availability of pyruvate for the TCA cycle, thereby lowering MCL of TCA cycle intermediates (Janzer et al., 2014) . However, as the ratio of lactate production to glucose consumption and the at-best small alterations in the MCL of cellular and extracellular lactate and alanine are not altered by the presence of metformin in cultured astrocytes, a lowering of pyruvate availability for mitochondrial metabolism appears, at least for astrocytes, unlikely to contribute to the observed reduction of TCA cycle activity. Therefore, it appears unlikely that the accelerated glycolytic flux in metformin-treated astrocytes is causing the observed decline in TCA cycle activity but, rather, that the metformin-induced alteration in mitochondrial metabolism is likely to cause the acceleration of glycolytic flux. This is consistent with a stimulation of PDH by trichloroacetate (Schmidt et al., 2011) , which did not modulate the metformin-induced stimulation of glycolytic flux (Westhaus et al., 2017) . In addition, at least for isolated muscle tissue from metformin-treated mice, PDH expression and activity were not changed, nor was citrate synthase activity (Kristensen et al., 2013) .
In rat liver mitochondrial lysates, metformin inhibited mitochondrial glycerophosphate dehydrogenase, causing an altered redox state, which reduces the use of lactate as a substrate for the production of glucose via gluconeogenesis (Madiraju et al., 2014) . Whether such an inhibition may also contribute to the increased glycolysis and decreased TCA cycle activity and decreased respiration in cultured astrocytes, and which role the mitochondrial glycerophosphate dehydrogenase could play in the metabolism of astrocytes, remains to be elucidated (McKenna et al., 2006) . Mitochondrial glycerophosphate dehydrogenase has been shown to be expressed in gray matter in brain sections (Nguyen et al., 2003) , but the expression of mitochondrial glycerophosphate dehydrogenase has not been demonstrated yet in cultured astrocytes.
In metformin-treated astrocytes, the complex Idriven mitochondrial oxygen consumption was almost completely inhibited, while oxygen consumption in the presence of complex II substrate was not affected. This observation is consistent with literature data reporting that metformin inhibits the respiratory chain complex I in hepatocytes and isolated liver mitochondria (El-Mir et al., 2000; Owen et al., 2000) as well as the isolated bovine heart complex I (Bridges et al., 2014) . Mechanistically, metformin may bind to the interface of the hydrophilic and membrane domains, thereby trapping complex I in a deactivated conformation and inhibiting ubiquinone reduction (Bridges et al., 2014) . The observation that mitochondrial oxygen consumption after application of the complex II substrate succinate is not affected in mitochondria isolated from metformin-treated astrocytes suggests that only complex I of the respiratory chain (and not other functional components of the respiratory chain) is impaired by metformin.
Inhibition of complex I leads to a decrease in the rate of mitochondrial oxidation of NADH, which is predominately generated by PDH and oxidoreductases of the TCA cycle. The extent of isotopomer labeling of the TCA cycle intermediates and amino acids is more reduced than the corresponding cycling ratios. This suggests that the increase in NADH due to complex I inhibition might activate PDH kinase, an enzyme that phosphorylates the E1 subunit of the PDH complex and thus decreases PDH activity (Roche et al., 2001 ). This impairment of NADH oxidation might thus initially inhibit the entrance of labeling into the TCA cycle and subsequently slow down the activity of the TCA cycle due to limited regeneration of the electron acceptor NAD 1 , explaining the severely lowered metabolic labeling of TCA intermediates in metformin-treated astrocytes compared with control cells. This is supported by the observation that other inhibitors of mitochondrial respiration also have been reported to slow down TCA cycle activity in astrocytes (McKenna et al., 1990 ) and a cancer cell line (Mullen et al., 2012) . The inhibition of initial carbon entrance into the TCA cycle is further supported by the comparable cycling ratios of control and metformin-treated astrocytes of the TCA cycle intermediates citrate, a-KG, succinate, and fumarate.
The inhibition of complex I by metformin is also likely to contribute to the stimulation of glycolytic flux by metformin (Westhaus et al., 2017) given that other inhibitors of mitochondrial respiration (e.g., rotenone) stimulate glycolytic flux in cultured astrocytes (Almeida et al., 2004; Schmidt et al., 2011; Tulpule and Dringen, 2012; Brandmann et al., 2013; Westhaus et al., 2017) .
The molecular mechanisms involved in the stimulation of cellular glycolytic flux by metformin are not fully understood. For hepatocytes and rat skeletal muscles, an involvement of the AMPK in the stimulation of glycolysis by metformin has been proposed (Zhou et al., 2001) , but this has been debated (Pryor and Cabreiro, 2015) . Cultured mouse astrocytes express AMPK, and in these cells the AMPK activation affects glutamate metabolism (Voss et al., 2015) . However, as the AMPK inhibitor compound C does not affect the basal or metforminstimulated glycolytic flux in cultured astrocytes (Allaman et al., 2015; Westhaus et al., 2017) , the observed acceleration by metformin of glucose consumption and lactate release appears to not involve AMPK. Impaired gluconeogenesis by AMP-and fructose-2,6-bisphosphatedependent inhibition of fructose 1,6-bisphosphatase has been suggested as an AMPK-independent mechanism involved in metformin-dependent glycolysis stimulation in primary hepatocytes (Pryor and Cabreiro, 2015) .
Interaction between glycolysis and mitochondrial metabolism also involves the transfer of electrons between these compartments, which depends on the NADH/ NAD 1 ratio in the two compartments (Hirrlinger and Dringen, 2010; Winkler and Hirrlinger, 2015) and can be mediated by the glycerophosphate shuttle and/or the malate-aspartate shuttle (McKenna et al., 1993 (McKenna et al., , 2006 . For cultured astrocytes, evidence for an efficient malateaspartate shuttle was presented (Fitzpatrick et al., 1983; Lai et al., 1989; Li et al., 2012) , while the role of the glycerophosphate shuttle remains to be elucidated (McKenna et al., 2006) . Especially the latter enzyme should be considered in the context of the observed metformin effects as mitochondrial glycerophosphate dehydrogenase has been shown to be inhibited by metformin (Madiraju et al., 2014) . As metformin treatment inactivates complex I-dependent respiration, the potential of the malateaspartate shuttle to shuttle electrons from glycolytically generated NADH into mitochondrial metabolism would be impaired because of a lowered oxidation of NADH by complex I. In contrast, the glycerophosphate shuttle would transfer cytosolic electrons via the FAD-containing mitochondrial glycerophosphate dehydrogenase directly to ubiquinone, bypassing complex I. However, as this enzyme is inactivated by metformin (Madiraju et al., 2014) , such an electron shuttle is also unlikely to take place. Thus, metformin is likely to slow down the transfer of glycolytically derived reduced equivalents into the mitochondria of astrocytes, thereby forcing the cells to use these electrons for the reduction of pyruvate to lactate to regenerate the NAD 1 required as an electron acceptor for glycolysis.
In addition to the decreased labeling of TCA cycle intermediates, the labeling of the cellular amino acids glutamate, aspartate, and glutamine was significantly lowered. This is most likely a direct consequence of the decreases in the labeling of TCA cycle intermediates, as TCA cycle intermediates are precursors for these amino acids (Fig. 1) . Also, for metformin-treated patients, a lowering in the plasma concentrations of amino acids was observed (Irving et al., 2015) , confirming that metformin treatment may affect amino acid homeostasis. As astrocytes have important functions in the amino acid metabolism of the brain-for example, by providing glutamine to neurons (Hassel et al., 1997; Broer and Brookes, 2001 )-metformin-induced alterations in such processes could strongly affect brain function and should be elucidated in detail in future studies, especially for the human brain.
In conclusion, adding to the known stimulation of astrocytic lactate production (Westhaus et al., 2017) , metformin strongly impaired mitochondrial respiration in the presence of complex I substrates and decreased the incorporation of 13 C-labeled carbon into intermediates of the TCA cycle under the conditions used. These data suggest that impairment of mitochondrial respiration is a primary event taking place in metformin-exposed astrocytes, which subsequently causes the observed decline in carbon entrance into the TCA cycle as well as the acceleration of glycolytic lactate production.
